

***Fiscal Year 2021 Alcohol and Substance Abuse Disorder Research Program (ASADRP)
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Consortium Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-21-ASADRP-CA</p>	<p>Independent intramural (DOD) and extramural Investigators at all academic levels (or equivalent).</p>	<ul style="list-style-type: none"> • Supports a Consortium to identify promising compounds; conduct proof-of-principle basic research and conduct human proof-of-concept trials with promising compounds to address effective treatments for Alcohol and Substance Use Disorders, to include reducing the overall number of opioid-related overdose death. • The Consortium will consist of a single management core as well as basic research and clinical trial sites. 	<ul style="list-style-type: none"> • The maximum period of performance is 5 years. • The CDMRP expects to allocate FY21-23 funding, if appropriated, to fund approximately one ASADRP Consortium Award. • The ASADRP Consortium will be funded initially with allocations from the FY21 ASADRP congressional appropriation (\$3.525M). • The maximum allowable total costs (direct and indirect) for the entire period of performance are \$10.575M (initial period of performance plus 2 options). • Two additional options, to be included in the application, may be funded from allocations from the FY22 and FY23 congressional appropriation (up to \$3.525M each year) subject to Programmatic Panel review, approval of the Grants Officer, and receipt of future congressional appropriations. 	<p>Pre-Application (Letter of Intent): August 18, 2021 5:00 p.m. Eastern time (ET)</p> <p>Application: September 8, 2021 11:59 p.m. ET</p>